Table 2 Virologic and biochemical response to entecavir.
From: A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients
NA-naïve (n = 33) | LAM-experienced (n = 21) | ADV-experienced (n = 33) | |||
|---|---|---|---|---|---|
No LAM-resistance (n = 11) | Prior history LAM-Resistance (n = 10) | Partial virology response (n = 4) | primary treatment failure (n = 29) | ||
Baseline HBV DNA(log10IU/ml) | 6.2 ± 1.9 | 7.0 ± 1.5 | 5.4 ± 1.9 | 3.5 ± 1.4 | 5.6 ± 1.4 |
Median follow-up (y) | 5.75 (5–6.25) | 6 (1.5–6.25) | 5 (1.75–6) | 5.75 (5–6) | 4.25(1–5.75) |
ALT normalization | 18/18 (100%) | 2/3 (67%) | 3/3 (100%) | 0/0 | 6/8 (75%) |
Virologic response | |||||
1 year | 28/33 (85%) | 7/11 (64%) | 6/10 (60%) | 4/4 (100%) | 14/29 (48%) |
2 year | 30/33 (91%) | 7/10 (70%) | 6/8 (75%) | 4/4 (100%) | 16/28 (57%) |
3 year | 32/33 (97%) | 7/10 (70%) | 6/7 (86%) | 4/4 (100%) | 20/28 (71%) |
4 year | 32/33 (97%) | 8/10 (80%) | 7/7 (100%) | 3/3 (100%) | 27/27 (100%) |
5 year | 33/33 (100%) | 8/10 (80%) | 6/6 (100%) | 3/3 (100%) | 10/10 (100%) |
Virologic breakthrough | |||||
1 year | 0/33 (0%) | 0/11 (0%) | 0/10 (0%) | 0/4 (0%) | 0/29 (0%) |
2 year | 0/33 (0%) | 2/10 (20%) | 2/8 (25%) | 0/4 (0%) | 0/29 (0%) |
3 year | 0/33 (0%) | 3/10 (30%) | 3/7 (43%) | 0/4 (0%) | 0/29 (0%) |
4 year | 0/33 (0%) | 3/10 (30%) | 3/7 (43%) | 1/4 (25%) | 0/29 (0%) |
5 year | 0/33 (0%) | 3/10 (30%) | 4/6 (67%) | 1/4 (25%) | 0/29 (0%) |
6 year | 0/33 (0%) | 3/10 (30%) | 4/6 (67%) | 1/4 (25%) | 1/29 (3%) |
Genotypic ETV-resistance | 0/33 (0%) | 3/11 (27%) | 4/10 (40%) | 1/4 (25%) | 1/29 (3%) |
HBeAg loss | 6/18 (33%) | 1/8 (13%) | 1/7 (14%) | 1/4 (25%) | 6/27 (22%) |
1 year | 1/18 (6%) | 0/8 (0%) | 1/7 (14%) | 0/4 (0%) | 1/26 (4%) |
2 year | 3/18 (17%) | 1/7 (14%) | 1/7 (14%) | 0/4 (0%) | 2/25 (8%) |
3 year | 5/18 (28%) | 1/7 (14%) | 1/7 (14%) | 0/4 (0%) | 4/25 (16%) |
4 year | 5/18 (28%) | 1/7 (14%) | 1/7 (14%) | 0/4 (0%) | 4/24 (17%) |
5 year | 6/18 (33%) | 1/7 (14%) | 1/7 (14%) | 1/4 (25%) | 3/10 (30%) |
HBsAg loss | 0/33 (0%) | 0/11 (0%) | 0/10 (0%) | 0/4 (0%) | 0/29 (0%) |
